{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:jim_chen.jpeg|frameless|upright=0.3|center]]
|<big>[[User:Jimchen|James L. Chen, MD, MS]]<br>Columbus, OH</big><br>[https://www.linkedin.com/in/jameschen777/ LinkedIn]
|-
|}
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=
==[http://www.esmo.org/ ESMO]==
*'''2014:''' [http://annonc.oxfordjournals.org/content/25/suppl_3/iii113.full.pdf+html Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.] [https://www.ncbi.nlm.nih.gov/pubmed/25210081 PubMed]
==ESMO/PaedCan/EURACAN==
*'''2018:''' Casali et al. [https://www.esmo.org/Guidelines/Sarcoma-and-GIST/Bone-Sarcomas Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up]
==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf NCCN Guidelines - Bone Cancer]

=Neoadjuvant therapy=

==Cisplatin & Doxorubicin {{#subobject:ae685c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
AP: '''<u>A</u>'''driamycin (Doxorubicin) & '''<u>P</u>'''latinol (Cisplatin)
===Variant #1 {{#subobject:248bc1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/10/10/1579.long Bramwell et al. 1992]
|style="background-color:#1a9851"|Phase III (E)
|[[#MAP|MAP]]
|style="background-color:#91cf60"|Seems to have superior DFS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2897%2902307-6/fulltext Souhami et al. 1997]
|style="background-color:#1a9851"|Phase III (E)
|Multi-drug T10 protocol
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV bolus once per day on days 1 to 3

====Supportive medications====
*Prehydration: normal saline 400 mL/m<sup>2</sup> and D5W 400 mL/m<sup>2</sup> over 2 hours--the reference did not clarify if these two solutions are given at the same time
*The volume of fluid for cisplatin continuous infusion is 2400 mL/m<sup>2</sup> NS, with KCl 80 mEq/L and mannitol 32,000 mg/m<sup>2</sup>
*Posthydration: D5W 600 mL/m<sup>2</sup> over 6 hours, with KCl 20 mEq/L and mannitol 8000 mg/m<sup>2</sup>; and NS 600 mL/m<sup>2</sup> over 6 hours, with KCl 20 mEq/L, magnesium sulfate 2 mmol/L, and calcium gluconate 0.6 mmol/L--the reference did not clarify if these two solutions are given at the same time. Then D5W 600 mL/m<sup>2</sup> over 12 hours, with KCl 20 mEq/L and mannitol 8000 mg/m<sup>2</sup>.
*[[Furosemide (Lasix)]] 20 to 40 mg IV if urine output is less than 400 mL/m<sup>2</sup> over 6 hours

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*Definitive [[Surgery#Surgical_resection|surgery]] on week 9, then [[#Cisplatin_.26_Doxorubicin_2|adjuvant AP]] that starts 14 to 28 days after surgery

===Variant #2 {{#subobject:33e180|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jnci.oxfordjournals.org/content/99/2/112.full Lewis et al. 2007 (EORTC 80931)]
|style="background-color:#1a9851"|Phase III (C)
|Dose-intense Cisplatin & Doxorubicin
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 to 3

====Supportive medications====
*4 hours of prehydration prior to cisplatin
*24 hours of posthydration & mannitol after cisplatin
*Recommended that fluid for cisplatin is isotonic saline with potassium chloride and mannitol

'''21-day cycle for 2 cycles'''
====Subsequent treatment====
*Definitive [[Surgery#Surgical_resection|surgery]] in a 14-day window between cycles 2 & 3, then [[#Cisplatin_.26_Doxorubicin_2|adjuvant AP]]

===References===
# Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom AT, Voûte PA, Rouesse J, Spooner D, Craft AW, Somers R, Pringle J, Malcolm AJ, van der Eiiken J, Thomas D, Uscinska B, Machin D, van Glabbeke M. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992 Oct;10(10):1579-91. [http://jco.ascopubs.org/content/10/10/1579.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1403038 PubMed]
# Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, Wierzbicki R, Malcolm AJ, Kirkpatrick A, Uscinska BM, Van Glabbeke M, Machin D. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997 Sep 27;350(9082):911-7. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2897%2902307-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9314869 PubMed]
# '''EORTC 80931:''' Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH; MRC BO06 and EORTC 80931 collaborators; European Osteosarcoma Intergroup. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007 Jan 17;99(2):112-28. [http://jnci.oxfordjournals.org/content/99/2/112.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17227995 PubMed]

==Cisplatin, Epirubicin, Ifosfamide {{#subobject:57c6cd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:f6b024|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://content.karger.com/produktedb/produkte.asp?DOI=10.1159/000113017 Basaran et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV over 15 minutes once on day 1
*[[Ifosfamide (Ifex)]] 2000 mg/m<sup>2</sup> IV over 4 hours once per day on days 2 to 4, '''given with [[Mesna (Mesnex)]]'''

====Supportive medications====
*[[Mesna (Mesnex)]] 2000 mg/m<sup>2</sup> IV over 4 hours once per day on days 2 to 4, '''given with [[Ifosfamide (Ifex)]]'''
*Prehydration and posthydration with mannitol diuresis for [[Cisplatin (Platinol)]]

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Surgery#Surgical_resection|Surgery]], then [[#Cisplatin.2C_Epirubicin.2C_Ifosfamide_2|adjuvant cisplatin, epirubicin, ifosfamide]]

===References===
# Basaran M, Bavbek ES, Saglam S, Eralp L, Sakar B, Atalar AC, Bilgic B, Ozger H, Onat H. A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. Oncology. 2007;72(3-4):255-60. Epub 2008 Jan 10. [http://content.karger.com/produktedb/produkte.asp?DOI=10.1159/000113017 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18185020 PubMed]

==MA {{#subobject:770fb2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MA: High-dose '''<u>M</u>'''ethotrexate, '''<u>A</u>'''driamycin (Doxorubicin)

===Regimen {{#subobject:216b6e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ejcancer.com/article/S0959-8049(06)01072-0/fulltext Le Deley et al. 2007 (SFOP OS94)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Methotrexate.2C_Etoposide.2C_Ifosfamide|Methotrexate, Etoposide, Ifosfamide]]
|style="background-color:#fee08b"|Might have inferior EFS
|-
|}
====Chemotherapy====
*[[Methotrexate (MTX)]] 12,000 mg/m<sup>2</sup> IV over 4 hours once per week on weeks 1, 2, 3, 6, 7, 10, 11
**Given in D5W 1L with sodium bicarbonate 1 mEq/kg
*[[Doxorubicin (Adriamycin)]] 70 mg/m<sup>2</sup> IV over 6 hours once per week on weeks 4 & 8

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg PO Q6H x up to 11 doses on weeks 1, 2, 3, 6, 7, 10, 11, starting 20 hours after the completion of [[Methotrexate (MTX)]] infusion
*For methotrexate: hydration & urine alkalinization by PO and IV routes to maintain 1.6 L/m<sup>2</sup> urine output over the first 24 hours and 2 L/m<sup>2</sup> on days 2 & 3, with urine pH greater than 7
*Daily monitoring of methotrexate levels and creatinine

'''11-week course'''
====Subsequent treatment====
*[[Surgery#Surgical_resection|Surgery]] occurs during week 12, with risk-adapted treatment as follows:
**Patients with good response: [[#MA|Adjuvant MA]]
**Patients with poor response: [[#IE|Adjuvant IE]]

===References===
# Le Deley MC, Guinebretière JM, Gentet JC, Pacquement H, Pichon F, Marec-Bérard P, Entz-Werlé N, Schmitt C, Brugières L, Vanel D, Dupoüy N, Tabone MD, Kalifa C; Société Française d'Oncologie Pédiatrique (SFOP). SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007 Mar;43(4):752-61. Epub 2007 Jan 30. [https://www.ejcancer.com/article/S0959-8049(06)01072-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17267204 PubMed]

==MA-BCD {{#subobject:f7c8d9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MA-BCD: High-dose '''<u>M</u>'''ethotrexate, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>C</u>'''yclophosphamide, '''<u>D</u>'''actinomycin

===Regimen {{#subobject:fe9985|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/2/6/617.long Winkler et al. 1984 (COSS-80)]
|style="background-color:#1a9851"|Phase III (C)
|[[#MAP|MAP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: The exact schedule is unclear based on limited/conflicting information in the reference. For example, Figure 1 appears to depict high-dose methotrexate starting 2 weeks after adriamycin, but the text says that methotrexate begins after a 3-week rest period. Additionally, the diagram in Figure 1 implies that the later therapies are given 4 times (once, then repeated x 3 cycles), but based on the cumulative doses listed, they are only given for a total of 3 cycles. The optional interferon arm is omitted given lack of benefit seen in the study.''
====Chemotherapy, part 1====
*[[Doxorubicin (Adriamycin)]] 45 mg/m<sup>2</sup> IV bolus once per day on days 1 & 2

'''21-day course, then'''

====Chemotherapy, part 2====
''See note above about uncertainty about the exact schedule.''
*[[Methotrexate (MTX)]] 12,000 mg/m<sup>2</sup> (maximum dose of 20,000 mg) IV over 4 hours once per day on days 1 & 8
**MTX is dissolved at a concentration of 20,000 mg/L in a solution containing 5% glucose
*[[Bleomycin (Blenoxane)]] 12 mg/m<sup>2</sup> IV bolus once per day on days 15 & 16
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV bolus once per day on days 15 & 16
*[[Dactinomycin (Cosmegen)]] 0.45 mg/m<sup>2</sup> IV bolus once per day on days 15 & 16

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> PO Q6H x 12 hours once per day on days 2 & 9, starting 24 hours after the completion of methotrexate infusion; additional leucovorin used for delayed methotrexate elimination
*Sodium bicarbonate urine alkalinization prior to high-dose methotrexate
*NS 4.5 L/m<sup>2</sup> on day 1 after methotrexate; NS 3 L/m<sup>2</sup> on day 2, with adjustments made to keep urine pH greater than 7.4

'''35-day course, followed by:'''

====Chemotherapy, part 3====
''See note above about uncertainty about the exact schedule.''
*[[Methotrexate (MTX)]] 12,000 mg/m<sup>2</sup> (maximum dose of 20,000 mg) IV over 4 hours once per day on days 1, 8, 29, 36
**MTX is dissolved at a concentration of 20,000 mg/L in a solution containing 5% glucose
*[[Doxorubicin (Adriamycin)]] 45 mg/m<sup>2</sup> IV bolus once per day on days 15 & 16 (delayed during cycle 1 until after surgery)
*[[Bleomycin (Blenoxane)]] 12 mg/m<sup>2</sup> IV bolus once per day on days 43 & 44
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV bolus once per day on days 43 & 44
*[[Dactinomycin (Cosmegen)]] 0.45 mg/m<sup>2</sup> IV bolus once per day on days 43 & 44

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> PO Q6H x 12 hours once per day on days 2, 9, 30, 37, starting 24 hours after the completion of methotrexate infusion; additional leucovorin used for delayed methotrexate elimination
*Sodium bicarbonate urine alkalinization prior to high-dose methotrexate
*NS 4.5 L/m<sup>2</sup> on day 1 after methotrexate; NS 3 L/m<sup>2</sup> on day 2, with adjustments made to keep urine pH greater than 7.4

'''8-week cycle for 3 cycles, with surgery done during cycle 1 before doxorubicin'''; surgery is done 9 to 18 weeks after the start of chemotherapy

===References===
# '''COSS-80:''' Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, Brandeis W, Ebell W, Erttmann R, Göbel U, Havers W, Henze G, Hinderfeld L, Höcker P, Jobke A, Jürgens H, Kabisch H, Preusser P, Prindull G, Ramach W, Ritter J, Sekera J, Treuner J, Wist G, Landbeck G. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol. 1984 Jun;2(6):617-24. [http://jco.ascopubs.org/content/2/6/617.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/6202851 PubMed]

==MAP {{#subobject:c479f6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MAP: High-dose '''<u>M</u>'''ethotrexate, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>P</u>'''latinol (Cisplatin)
===Variant #1 {{#subobject:726dd7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/10/10/1579.long Bramwell et al. 1992]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Doxorubicin|Cisplatin & Doxorubicin]]
|style="background-color:#fc8d59"|Seems to have inferior DFS
|-
|}
''Note: The body of Bramwell et al. 1992 says that methotrexate is given over 4 hours, whereas Bramwell et al. 1992 figure 1's text says that methotrexate is given over 6 hours.''
====Chemotherapy====
*[[Methotrexate (MTX)]] 8000 mg/m<sup>2</sup> IV over 4 to 6 hours once on day 1
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV bolus once per day on days 11 to 13
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 11

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 12 mg/m<sup>2</sup> IV Q6H x 10 doses or 15 mg/m<sup>2</sup> PO Q6H x 10 doses, starting 24 hours after the start of [[Methotrexate (MTX)]] infusion
**Monitor methotrexate level at "24 hours and 48 hours"--it is unclear in the reference if this is time after the start/end of methotrexate, beginning of leucovorin, or something else
**Methotrexate levels higher than 100 nmol/L at 48 hours required additional leucovorin rescue
*Prehydration for methotrexate: "0.9 NaCl:D5W"--unclear if this means either normal saline or D5W can be used--750 mL/m<sup>2</sup> over 6 hours, with KCl 20 mEq/L
*The volume of fluid for methotrexate is D5W 1000 mL, to be given over 6 hours
*Posthydration for methotrexate: Alternating liters of D5W and NS 3000 mL/m<sup>2</sup> over 24 hours, with KCl 60 mEq/L.
*Sodium bicarbonate 3 g PO Q6H, starting 12 hours before methotrexate, and sodium bicarbonate 167 mmol/L IV until serum methotrexate level is less than 8000 to 10,000 nmol/L. Note: the reference is not clear about when/if PO sodium bicarbonate is stopped, when IV sodium bicarbonate is started, or the administration rate of IV sodium bicarbonate.
*Prehydration for [[Cisplatin (Platinol)]]: normal saline 400 mL/m<sup>2</sup> and D5W 400 mL/m<sup>2</sup> over 2 hours--the reference did not clarify if these two solutions are given at the same time
*The volume of fluid for cisplatin continuous infusion is 2400 mL/m<sup>2</sup> NS, with KCl 80 mEq/L and mannitol 32,000 mg/m<sup>2</sup>
*Posthydration for [[Cisplatin (Platinol)]]: D5W 600 mL/m<sup>2</sup> over 6 hours, with KCl 20 mEq/L and mannitol 8000 mg/m<sup>2</sup>; and NS 600 mL/m<sup>2</sup> over 6 hours, with KCl 20 mEq/L, magnesium sulfate 2 mmol/L, and calcium gluconate 0.6 mmol/L--the reference did not clarify if these two solutions are given at the same time. Then D5W 600 mL/m<sup>2</sup> over 12 hours, with KCl 20 mEq/L and mannitol 8000 mg/m<sup>2</sup>.
*[[Furosemide (Lasix)]] 20 to 40 mg IV if urine output is less than 400 mL/m<sup>2</sup> over 6 hours during [[Cisplatin (Platinol)]]

'''21-day cycle for 2 cycles'''
====Subsequent treatment====
*Definitive [[Surgery#Surgical_resection|surgery]] on week 9, then [[#MAP_2|adjuvant MAP]] that starts 14 to 28 days after surgery

===Variant #2 {{#subobject:9f5a4e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19931201)72:11%3C3227::AID-CNCR2820721116%3E3.0.CO;2-C/abstract Bacci et al. 1993 (IOR/OS-2)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Methotrexate (MTX)]] 8000 mg/m<sup>2</sup> IV over 6 hours once on day 1
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV over 8 hours once on day 9, '''starting 48 hours after the start of cisplatin'''
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup>/day IA continuous infusion over 72 hours, started on day 7 (total dose per cycle: 120 mg/m<sup>2</sup>)

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg IV Q6H x 11 doses on days 2 to 4, starting 24 hours after the start of [[Methotrexate (MTX)]] infusion
*Hydration during and after [[Methotrexate (MTX)]] infusion

'''27-day cycle for 2 cycles'''
====Subsequent treatment====
*Definitive [[Surgery#Surgical_resection|surgery]], then risk-adapted therapy. Amputated patients restart chemotherapy 3 to 5 days after surgery; patients who undergo limb salvage or rotation plasty restart chemotherapy 10 to 21 days after surgery.
**At least 90% tumor necrosis in the surgically removed specimen: [[#MAP_2|Adjuvant MAP]]
**Less than 90% tumor necrosis in the surgically removed specimen: [[#MAPIE|Adjuvant MAPIE]]

===Variant #3 {{#subobject:727eb0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/6/2/329.long Winkler et al. 1988 (COSS-82)]
|style="background-color:#1a9851"|Phase III (E)
|[[#M-BCD|M-BCD]]
|style="background-color:#1a9850"|Superior ORR
|-
|}
''Note: The exact schedule is unclear based on limited information in the reference, as schedule of doses is primarily extrapolated from Figure 1, which does not contain clear delineations in time. The dose/schedule of cisplatin reflects the protocol amendment that was done because of nephrotoxicity.''
====Chemotherapy====
*[[Methotrexate (MTX)]] 12,000 mg/m<sup>2</sup> (maximum dose of 20,000 mg) IV over 4 hours once per day on days 22 & 29
**MTX is dissolved at a concentration of 20,000 mg/L in a solution containing 5% glucose
*[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> IV bolus once per day on days 1 & 2
*[[Cisplatin (Platinol)]] 90 mg/m<sup>2</sup> IV over 4 hours once on day 3

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> PO Q6H x 12 hours once per day on days 23 & 30, starting 24 hours after the completion of [[Methotrexate (MTX)]] infusion; additional leucovorin used for delayed methotrexate elimination
*Sodium bicarbonate urine alkalinization prior to high-dose [[Methotrexate (MTX)]]
*NS 4.5 L/m<sup>2</sup> on day 1 after methotrexate; NS 3 L/m<sup>2</sup> on day 2, with adjustments made to keep urine pH greater than 7.4
*12 hours of hydration prior to [[Cisplatin (Platinol)]] & 20 hours of hydration after [[Cisplatin (Platinol)]]; total amount of fluid given over 36hours of prehydration, cisplatin, and posthydration is NS 6 L/m<sup>2</sup> with mannitol 8 g/L and potassium 20 mval/L.
*Magnesium 180 mg/m<sup>2</sup> PO "per day throughout the whole chemotherapy time"--as described in COSS-80

'''35-day cycle for 2 cycles'''
====Subsequent treatment====
*[[Surgery#Surgical_resection|Surgery]], then risk-adapted treatment:
**Good response: [[#MAP_2|Adjuvant MAP]]
**Poor response: [[#IP-BCD|adjuvant IP-BCD]]

===Variant #4 {{#subobject:267572|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/2/6/617.long Winkler et al. 1984 (COSS-80)]
|style="background-color:#1a9851"|Phase III (E)
|MA-BCD
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: The exact schedule is unclear based on limited/conflicting information in the reference. For example, Figure 1 appears to depict high-dose methotrexate starting 2 weeks after adriamycin, but the text says that methotrexate begins after a 3-week rest period. Additionally, the diagram in Figure 1 implies that the later therapies are given 4 times (once, then repeated x 3 cycles), but based on the cumulative doses listed, they are only given for a total of 3 cycles. The optional interferon arm is omitted given lack of benefit seen in the study.''
====Chemotherapy, part 1====
*[[Doxorubicin (Adriamycin)]] 45 mg/m<sup>2</sup> IV bolus once per day on days 1 & 2

'''21-day course, followed by:'''

====Chemotherapy, part 2====
''See note above about uncertainty about the exact schedule.''
*[[Methotrexate (MTX)]] 12,000 mg/m<sup>2</sup> (maximum dose of 20,000 mg) IV over 4 hours once per day on days 1 & 8
**MTX is dissolved at a concentration of 20,000 mg/L in a solution containing 5% glucose
*[[Cisplatin (Platinol)]] 120 mg/m<sup>2</sup> IV over 5 hours once on day 15

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> PO Q6H x 12 hours once per day on days 2 & 9, starting 24 hours after the completion of [[Methotrexate (MTX)]] infusion; additional leucovorin used for delayed methotrexate elimination
*Sodium bicarbonate urine alkalinization prior to high-dose [[Methotrexate (MTX)]]
*NS 4.5 L/m<sup>2</sup> on day 1 after [[Methotrexate (MTX)]]; NS 3 L/m<sup>2</sup> on day 2, with adjustments made to keep urine pH greater than 7.4
*3 hours of hydration prior to [[Cisplatin (Platinol)]] & 3 hours of hydration after [[Cisplatin (Platinol)]]; total amount of fluid given over 11 hours of prehydration, cisplatin, and posthydration is NS 2.5 L/m<sup>2</sup> with mannitol 8 g/L and potassium 20 mval/L.
*Magnesium 180 mg/m<sup>2</sup> PO "per day throughout the whole chemotherapy time" with [[Cisplatin (Platinol)]]

'''35-day course, followed by:'''

====Chemotherapy, part 3====
''See note above about uncertainty about the exact schedule.''
*[[Methotrexate (MTX)]] 12,000 mg/m<sup>2</sup> (maximum dose of 20,000 mg) IV over 4 hours once per day on days 1, 8, 29, 36
**MTX is dissolved at a concentration of 20,000 mg/L in a solution containing 5% glucose
*[[Doxorubicin (Adriamycin)]] 45 mg/m<sup>2</sup> IV bolus once per day on days 15 & 16 (delayed during cycle 1 until after surgery)
*[[Cisplatin (Platinol)]] 120 mg/m<sup>2</sup> IV over 5 hours once on day 43

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> PO Q6H x 12 hours once per day on days 2, 9, 30, 37, starting 24 hours after the completion of [[Methotrexate (MTX)]] infusion; additional leucovorin used for delayed methotrexate elimination
*Sodium bicarbonate urine alkalinization prior to high-dose [[Methotrexate (MTX)]]
*NS 4.5 L/m<sup>2</sup> on day 1 after [[Methotrexate (MTX)]]; NS 3 L/m<sup>2</sup> on day 2, with adjustments made to keep urine pH greater than 7.4
*3 hours of hydration prior to [[Cisplatin (Platinol)]] & 3 hours of hydration after [[Cisplatin (Platinol)]]; total amount of fluid given over 11 hours of prehydration, cisplatin, and posthydration is NS 2.5 L/m<sup>2</sup> with mannitol 8 g/L and potassium 20 mval/L.
*Magnesium 180 mg/m<sup>2</sup> PO "per day throughout the whole chemotherapy time" with [[Cisplatin (Platinol)]]

'''8-week cycle for 3 cycles, with surgery done during cycle 1 before doxorubicin'''; surgery is done 9 to 18 weeks after the start of chemotherapy

===References===
# '''COSS-80:''' Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, Brandeis W, Ebell W, Erttmann R, Göbel U, Havers W, Henze G, Hinderfeld L, Höcker P, Jobke A, Jürgens H, Kabisch H, Preusser P, Prindull G, Ramach W, Ritter J, Sekera J, Treuner J, Wist G, Landbeck G. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol. 1984 Jun;2(6):617-24. [http://jco.ascopubs.org/content/2/6/617.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/6202851 PubMed]
# '''COSS-82:''' Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, Berger J, Ritter J, Jürgens H, Gerein V, Graf N, Russe W, Gruemayer ER, Ertelt W, Kotz R, Preuzzer P, Prindull G, Brandeis W, Landbeck G. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988 Feb;6(2):329-37. [http://jco.ascopubs.org/content/6/2/329.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2448428 PubMed]
# Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom AT, Voûte PA, Rouesse J, Spooner D, Craft AW, Somers R, Pringle J, Malcolm AJ, van der Eiiken J, Thomas D, Uscinska B, Machin D, van Glabbeke M. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992 Oct;10(10):1579-91. [http://jco.ascopubs.org/content/10/10/1579.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1403038 PubMed] content property of [http://hemonc.org HemOnc.org]
# '''IOR/OS-2:''' Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, Brach del Prever A, Gherlinzoni F, Mercuri M, Monti C. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993 Dec 1;72(11):3227-38. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19931201)72:11%3C3227::AID-CNCR2820721116%3E3.0.CO;2-C/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8242546 PubMed]
## '''Update:''' Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M, Campanacci M. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000 Dec 15;18(24):4016-27. [http://jco.ascopubs.org/content/18/24/4016.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11118462 PubMed]

==MAPI {{#subobject:8fa44|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MAPI: High-dose '''<u>M</u>'''ethotrexate, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>P</u>'''latinol (Cisplatin), '''<u>I</u>'''fosfamide
===Regimen {{#subobject:ad261e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/14/7/1126.long Bacci et al. 2003]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Methotrexate (MTX)]] 12,000 mg/m<sup>2</sup> IV over 4 hours once on day 1
**If 4-hour methotrexate level is less than 10,000 nmol/L, the next cycle's dose is increased by 2000 mg/m<sup>2</sup>
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup>/day IV continuous infusion over 48 hours, started on day 8 (total dose per cycle: 120 mg/m<sup>2</sup>)
*[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 10
*[[Ifosfamide (Ifex)]] 3000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 29, '''given with [[Mesna (Mesnex)]]''' (total dose per cycle: 15,000 mg/m<sup>2</sup>)

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg (route not specified) Q6H x 11 doses (note: the reference says "11 cycles," but it is assumed this is the intended meaning), starting day 2, 24 hours after the start of [[Methotrexate (MTX)]]
*Hydration during and after methotrexate as described by: Rosen G, Nirenberg A. Chemotherapy for osteogenic sarcoma: an investigative method, not a recipe. Cancer Treat Rep. 1982 Sep;66(9):1687-97. [https://www.ncbi.nlm.nih.gov/pubmed/6981454 PubMed]
*[[Mesna (Mesnex)]] 3000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 29, '''given with [[Ifosfamide (Ifex)]]''' (total dose: 15,000 mg/m<sup>2</sup>)

'''42-day cycle for 2 cycles'''
====Subsequent treatment====
*[[Surgery#Surgical_resection|Surgery]], then [[#MAPI_2|adjuvant MAPI]]

===References===
# Bacci G, Briccoli A, Rocca M, Ferrari S, Donati D, Longhi A, Bertoni F, Bacchini P, Giacomini S, Forni C, Manfrini M, Galletti S. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 2003 Jul;14(7):1126-34. [http://annonc.oxfordjournals.org/content/14/7/1126.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12853357 PubMed]

==M-BCD {{#subobject:6f3563|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
M-BCD: High-dose '''<u>M</u>'''ethotrexate, '''<u>B</u>'''leomycin, '''<u>C</u>'''yclophosphamide, '''<u>D</u>'''actinomycin

===Regimen {{#subobject:8ea4f8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/6/2/329.long Winkler et al. 1988 (COSS-82)]
|style="background-color:#1a9851"|Phase III (C)
|[[#MAP|MAP]]
|style="background-color:#d73027"|Inferior ORR
|-
|}
''Note: The exact schedule is unclear based on limited information in the reference, as schedule of doses is primarily extrapolated from Figure 1, which does not contain clear delineations in time.''
====Chemotherapy====
*[[Methotrexate (MTX)]] 12,000 mg/m<sup>2</sup> (maximum dose of 20,000 mg) IV over 4 hours once per day on days 15 & 22
**MTX is dissolved at a concentration of 20,000 mg/L in a solution containing 5% glucose
*[[Bleomycin (Blenoxane)]] 15 mg/m<sup>2</sup> IV bolus once per day on days 1 & 2
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV bolus once per day on days 1 & 2
*[[Dactinomycin (Cosmegen)]] 0.6 mg/m<sup>2</sup> IV bolus once per day on days 1 & 2

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> PO Q6H x 12 hours once per day on days 16 & 23, starting 24 hours after the completion of methotrexate infusion; additional leucovorin used for delayed methotrexate elimination
*Sodium bicarbonate urine alkalinization prior to high-dose [[Methotrexate (MTX)]]
*NS 4.5 L/m<sup>2</sup> on day 1 after [[Methotrexate (MTX)]]; NS 3 L/m<sup>2</sup> on day 2, with adjustments made to keep urine pH greater than 7.4

'''35-day cycle for 2 cycles'''
====Subsequent treatment====
*[[Surgery#Surgical_resection|Surgery]], then risk-adapted treatment:
**Patients who had a good response: [[#M-BCD_2|Adjuvant M-BCD]]
**Patients who had a poor response: [[#Cisplatin_.26_Doxorubicin_2|Adjuvant AP]]

===References===
# '''COSS-82:''' Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, Berger J, Ritter J, Jürgens H, Gerein V, Graf N, Russe W, Gruemayer ER, Ertelt W, Kotz R, Preuzzer P, Prindull G, Brandeis W, Landbeck G. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988 Feb;6(2):329-37. [http://jco.ascopubs.org/content/6/2/329.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2448428 PubMed]

==M-EI {{#subobject:ac6075|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
M-EI: '''<u>M</u>'''ethotrexate, '''<u>E</u>'''toposide, '''<u>I</u>'''fosfamide
===Regimen {{#subobject:9ed88a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ejcancer.com/article/S0959-8049(06)01072-0/fulltext Le Deley et al. 2007 (SFOP OS94)]
|style="background-color:#1a9851"|Phase III (E)
|[[#MA|MA]]
|style="background-color:#d9ef8b"|Might have superior EFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30096-1/fulltext Piperno-Neumann et al. 2016 (OS2006)]
|style="background-color:#1a9851"|Phase III (C)
|M-EI & Zoledronic acid
|style="background-color:#d9ef8b"|Might have superior EFS
|-
|}
''Note: this regimen information is from SFOP OS94.''
====Chemotherapy====
*[[Methotrexate (MTX)]] 12,000 mg/m<sup>2</sup> IV over 4 hours once per week on weeks 1, 2, 3, 7, 8, 12, 13
**Given in D5W 1L with sodium bicarbonate 1 mEq/kg
*[[Etoposide (Vepesid)]] 75 mg/m<sup>2</sup> IV over 60 minutes once per day on days 22 to 25 (week 4), 57 to 60 (week 9)
**Given in NS 250 to 500 mL
*[[Ifosfamide (Ifex)]] 3000 mg/m<sup>2</sup> IV over 3 hours once per day on days 22 to 25 (week 4), 57 to 60 (week 9), '''given with [[Mesna (Mesnex)]]'''
**Given in NS 250 to 500 mL

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg PO Q6H x up to 11 doses on weeks 1, 2, 3, 7, 8, 12, 13, starting 20 hours after the completion of methotrexate infusion
*For methotrexate: hydration & urine alkalinization by PO and IV routes to maintain 1.6 L/m<sup>2</sup> urine output over the first 24 hours and 2 L/m<sup>2</sup> on days 2 & 3, with urine pH greater than 7
*Daily monitoring of methotrexate levels and creatinine
*[[Mesna (Mesnex)]] 3600 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 22 (week 4) and 57 (week 9), '''given with [[Ifosfamide (Ifex)]]''' (total dose: 14,400 mg/m<sup>2</sup>)
*Up to 2 L/day hydration with ifosfamide & mesna
====Subsequent treatment====
*[[Surgery#Surgical_resection|Surgery]] occurs during week 14, with further treatment based on pathologic response:
**Patients with good response: [[#M-EI_2|Adjuvant M-EI]]
**Patients with poor response: [[#Cisplatin_.26_Doxorubicin_2|Adjuvant AP]]

===References===
# '''SFOP OS94:''' Le Deley MC, Guinebretière JM, Gentet JC, Pacquement H, Pichon F, Marec-Bérard P, Entz-Werlé N, Schmitt C, Brugières L, Vanel D, Dupoüy N, Tabone MD, Kalifa C; Société Française d'Oncologie Pédiatrique (SFOP). SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007 Mar;43(4):752-61. Epub 2007 Jan 30. [https://www.ejcancer.com/article/S0959-8049(06)01072-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17267204 PubMed]
# '''OS2006:''' Piperno-Neumann S, Le Deley MC, Rédini F, Pacquement H, Marec-Bérard P, Petit P, Brisse H, Lervat C, Gentet JC, Entz-Werlé N, Italiano A, Corradini N, Bompas E, Penel N, Tabone MD, Gomez-Brouchet A, Guinebretière JM, Mascard E, Gouin F, Chevance A, Bonnet N, Blay JY, Brugières L; Sarcoma Group of UNICANCER; French Society of Pediatric Oncology (SFCE); French Sarcoma Group (GSF-GETO). Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016 Aug;17(8):1070-1080. Epub 2016 Jun 17. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30096-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27324280 PubMed]
## '''Update:''' Gaspar N, Occean BV, Pacquement H, Bompas E, Bouvier C, Brisse HJ, Castex MP, Cheurfa N, Corradini N, Delaye J, Entz-Werlé N, Gentet JC, Italiano A, Lervat C, Marec-Berard P, Mascard E, Redini F, Saumet L, Schmitt C, Tabone MD, Verite-Goulard C, Le Deley MC, Piperno-Neumann S, Brugieres L; SFCE (Société Française des Cancers de l'Enfant et l'adolescent); GSF-GETO (Groupe Sarcome Français); UNICANCER sarcoma group. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. Eur J Cancer. 2018 Jan;88:57-66. Epub 2017 Nov 28. [https://www.ejcancer.com/article/S0959-8049(17)31339-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29190507 PubMed]

=Adjuvant therapy=

==Cisplatin & Doxorubicin {{#subobject:267127|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
AP: '''<u>A</u>'''driamycin (Doxorubicin) & '''<u>P</u>'''latinol (Cisplatin)
===Variant #1 {{#subobject:602292|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/10/10/1579.long Bramwell et al. 1992]
|style="background-color:#1a9851"|Phase III (E)
|[[#MAP|MAP]]
|style="background-color:#91cf60"|Seems to have superior DFS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2897%2902307-6/fulltext Souhami et al. 1997]
|style="background-color:#1a9851"|Phase III (E)
|Multi-drug T10 protocol
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Preceding treatment====
*[[#Cisplatin_.26_Doxorubicin|Neoadjuvant AP]], then [[Surgery#Surgical_resection|surgery]]
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV bolus once per day on days 1 to 3

====Supportive medications====
*Prehydration: normal saline 400 mL/m<sup>2</sup> and D5W 400 mL/m<sup>2</sup> over 2 hours--the reference did not clarify if these two solutions are given at the same time
*The volume of fluid for cisplatin continuous infusion is 2400 mL/m<sup>2</sup> NS, with KCl 80 mEq/L and mannitol 32,000 mg/m<sup>2</sup>
*Posthydration: D5W 600 mL/m<sup>2</sup> over 6 hours, with KCl 20 mEq/L and mannitol 8000 mg/m<sup>2</sup>; and NS 600 mL/m<sup>2</sup> over 6 hours, with KCl 20 mEq/L, magnesium sulfate 2 mmol/L, and calcium gluconate 0.6 mmol/L--the reference did not clarify if these two solutions are given at the same time. Then D5W 600 mL/m<sup>2</sup> over 12 hours, with KCl 20 mEq/L and mannitol 8000 mg/m<sup>2</sup>.
*[[Furosemide (Lasix)]] 20 to 40 mg IV if urine output is less than 400 mL/m<sup>2</sup> over 6 hours

'''21-day cycle for 3 cycles'''

===Variant #2 {{#subobject:32db86|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jnci.oxfordjournals.org/content/99/2/112.full Lewis et al. 2007]
|style="background-color:#1a9851"|Phase III (C)
|Dose-intense Cisplatin & Doxorubicin
|style="background-color:#d73027"|Inferior good histologic response rate
|-
|}
====Preceding treatment====
*[[#Cisplatin_.26_Doxorubicin|Neoadjuvant AP]], then [[Surgery#Surgical_resection|surgery]]
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 to 3

====Supportive medications====
*4 hours of prehydration prior to cisplatin
*24 hours of posthydration & mannitol after cisplatin
*Recommended that fluid for cisplatin is isotonic saline with potassium chloride and mannitol

'''21-day cycle for 4 cycles'''

===Variant #3, dose intense {{#subobject:d1ecd3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jnci.oxfordjournals.org/content/99/2/112.full Lewis et al. 2007 (EORTC 80931)]
|style="background-color:#1a9851"|Phase III (E)
|Conventional Cisplatin & Doxorubicin
|style="background-color:#1a9850"|Superior good histologic response rate
|-
|}
====Preceding treatment====
*[[#Cisplatin_.26_Doxorubicin|Neoadjuvant AP]], then [[Surgery#Surgical_resection|surgery]]
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 to 3

====Supportive medications====
*Growth factor suppor with ONE of the following:
**[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 4 to 13
**[[Lenograstim (Granocyte)]] 5 mcg/kg SC once per day on days 4 to 13
*4 hours of prehydration prior to [[Cisplatin (Platinol)]]
*24 hours of posthydration & mannitol after [[Cisplatin (Platinol)]]
*Recommended that fluid for cisplatin is isotonic saline with potassium chloride and mannitol

'''14-day cycle for 3 cycles'''

===Variant #4 {{#subobject:44bba3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/6/2/329.long Winkler et al. 1988 (COSS-82)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Note: The exact schedule is unclear based on limited information in the reference, as schedule of doses is primarily extrapolated from Figure 1, which does not contain clear delineations in time.''
====Preceding treatment====
*[[#M-BCD|Neoadjuvant M-BCD]], then [[Surgery#Surgical_resection|surgery]], with poor response
====Chemotherapy====
*[[Cisplatin (Platinol)]] 90 mg/m<sup>2</sup> IV over 4 hours once on day 3
*[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> IV bolus once per day on days 1 & 2

====Supportive medications====
*12 hours of hydration prior to cisplatin & 20 hours of hydration after cisplatin; total amount of fluid given over 36hours of prehydration, cisplatin, and posthydration is NS 6 L/m<sup>2</sup> with mannitol 8 g/L and potassium 20 mval/L.
*Magnesium 180 mg/m<sup>2</sup> PO "per day throughout the whole chemotherapy time"--as described in COSS-80

'''21-day cycle for 6 cycles'''

===Variant #5 {{#subobject:7fc4e3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ejcancer.com/article/S0959-8049(06)01072-0/abstract Le Deley et al. 2007 (SFOP OS94)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Details were not listed about the precise schedule. Other regimens have used both medications both on day 1, with 21-day cycles.''
====Preceding treatment====
*[[#M-EI|Neoadjuvant M-EI]], then [[Surgery#Surgical_resection|surgery]], with poor response
====Chemotherapy====
*[[Cisplatin (Platinol)]] 120 mg/m<sup>2</sup>
*[[Doxorubicin (Adriamycin)]] 70 mg/m<sup>2</sup> IV over 6 hours
 
'''5 cycles'''

===References===
# '''COSS-82:''' Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, Berger J, Ritter J, Jürgens H, Gerein V, Graf N, Russe W, Gruemayer ER, Ertelt W, Kotz R, Preuzzer P, Prindull G, Brandeis W, Landbeck G. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988 Feb;6(2):329-37. [http://jco.ascopubs.org/content/6/2/329.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2448428 PubMed]
# Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom AT, Voûte PA, Rouesse J, Spooner D, Craft AW, Somers R, Pringle J, Malcolm AJ, van der Eiiken J, Thomas D, Uscinska B, Machin D, van Glabbeke M. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992 Oct;10(10):1579-91. [http://jco.ascopubs.org/content/10/10/1579.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1403038 PubMed]
# Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, Wierzbicki R, Malcolm AJ, Kirkpatrick A, Uscinska BM, Van Glabbeke M, Machin D. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997 Sep 27;350(9082):911-7. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2897%2902307-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9314869 PubMed]
# '''EORTC 80931:''' Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH; MRC BO06 and EORTC 80931 collaborators; European Osteosarcoma Intergroup. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007 Jan 17;99(2):112-28. [http://jnci.oxfordjournals.org/content/99/2/112.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17227995 PubMed]
# '''SFOP OS94:''' Le Deley MC, Guinebretière JM, Gentet JC, Pacquement H, Pichon F, Marec-Bérard P, Entz-Werlé N, Schmitt C, Brugières L, Vanel D, Dupoüy N, Tabone MD, Kalifa C; Société Française d'Oncologie Pédiatrique (SFOP). SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007 Mar;43(4):752-61. Epub 2007 Jan 30. [https://www.ejcancer.com/article/S0959-8049(06)01072-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17267204 PubMed]

==Cisplatin, Epirubicin, Ifosfamide {{#subobject:cd0e26|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:320a96|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://content.karger.com/produktedb/produkte.asp?DOI=10.1159/000113017 Basaran et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#Cisplatin.2C_Epirubicin.2C_Ifosfamide|Neoadjuvant cisplatin, epirubicin, ifosfamide]], then [[Surgery#Surgical_resection|surgery]]
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 2 hours
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV over 15 minutes once on day 1
*[[Ifosfamide (Ifex)]] 2000 mg/m<sup>2</sup> IV over 4 hours once per day on days 2 to 4, '''given with [[Mesna (Mesnex)]]'''

====Supportive medications====
*[[Mesna (Mesnex)]] 2000 mg/m<sup>2</sup> IV over 4 hours once per day on days 2 to 4, '''given with [[Ifosfamide (Ifex)]]'''
*Prehydration and posthydration with mannitol diuresis for [[Cisplatin (Platinol)]]

'''28-day cycle for 3 cycles'''

===References===
# Basaran M, Bavbek ES, Saglam S, Eralp L, Sakar B, Atalar AC, Bilgic B, Ozger H, Onat H. A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. Oncology. 2007;72(3-4):255-60. Epub 2008 Jan 10. [http://content.karger.com/produktedb/produkte.asp?DOI=10.1159/000113017 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18185020 PubMed]

==Doxorubicin monotherapy {{#subobject:681e0f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:81ee7b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM197411072911903 Cortes et al. 1974]
|style="background-color:#91cf61"|Non-randomized
|-
|}
''Of historic interest.''
====Preceding treatment====
*[[Surgery#Surgical_resection|Surgery]]
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> IV once per day on days 1 to 3

'''4- to 6-week cycle for 6 cycles'''
===References===
# Cortes EP, Holland JF, Wang JJ, Sinks LF, Blom J, Senn H, Bank A, Glidewell O. Amputation and adriamycin in primary osteosarcoma. N Engl J Med. 1974 Nov 7;291(19):998-1000. [https://www.nejm.org/doi/full/10.1056/NEJM197411072911903 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/4528415 PubMed]

==IE {{#subobject:777bc8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
IE: '''<u>I</u>'''fosfamide, '''<u>E</u>'''toposide

===Regimen {{#subobject:7d60b5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ejcancer.com/article/S0959-8049(06)01072-0/abstract Le Deley et al. 2007 (SFOP OS94)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Details were not listed about the length of each cycle. Other regimens have used 21 to 28-day cycles.''
====Preceding treatment====
*[[#MA|Neoadjuvant MA]], then [[Surgery#Surgical_resection|surgery]], with poor response
====Chemotherapy====
*[[Ifosfamide (Ifex)]] 3000 mg/m<sup>2</sup> IV over 3 hours once per day on days 1 to 4, '''given during [[Mesna (Mesnex)]] infusion'''
**Given in NS 250 to 500 mL
*[[Etoposide (Vepesid)]] 75 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 4
**Given in NS 250 to 500 mL

====Supportive medications====
*[[Mesna (Mesnex)]] 3600 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose: 14,400 mg/m<sup>2</sup>)
*Up to 2 L/day hydration with ifosfamide & mesna

'''5 cycles'''

===References===
# Le Deley MC, Guinebretière JM, Gentet JC, Pacquement H, Pichon F, Marec-Bérard P, Entz-Werlé N, Schmitt C, Brugières L, Vanel D, Dupoüy N, Tabone MD, Kalifa C; Société Française d'Oncologie Pédiatrique (SFOP). SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007 Mar;43(4):752-61. Epub 2007 Jan 30. [https://www.ejcancer.com/article/S0959-8049(06)01072-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17267204 PubMed]

==IP-BCD {{#subobject:b45a8a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
IP-BCD: '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin), '''<u>B</u>'''leomycin, '''<u>C</u>'''yclophosphamide, '''<u>D</u>'''actinomycin

===Regimen {{#subobject:c70abe|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/6/2/329.long Winkler et al. 1988 (COSS-82)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#MAP|Neoadjuvant MAP]], then [[Surgery#Surgical_resection|surgery]], with poor response
====Chemotherapy====
*[[Ifosfamide (Ifex)]] 2000 mg/m<sup>2</sup> IV over 23.5 hours once per day on days 1 to 5, '''given second, with [[Mesna (Mesnex)]]'''
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5, '''given first'''
*[[Bleomycin (Blenoxane)]] 15 mg/m<sup>2</sup> IV bolus once per day on days 22 & 23
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV bolus once per day on days 22 & 23
*[[Dactinomycin (Cosmegen)]] 0.6 mg/m<sup>2</sup> IV bolus once per day on days 22 & 23

====Supportive medications====
*[[Mesna (Mesnex)]] 2000 mg/m<sup>2</sup> IV over 23.5 hours once per day on days 1 to 5, '''given second, with [[Ifosfamide (Ifex)]]''', then 2000 mg/m<sup>2</sup>/day IV continuous infusion over 48 hours, started on day 6 (total dose: 14,000 mg/m<sup>2</sup>)
*Mannitol given with [[Cisplatin (Platinol)]]; no further details provided

'''35-day cycle for 3 cycles'''

===References===
# '''COSS-82:''' Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, Berger J, Ritter J, Jürgens H, Gerein V, Graf N, Russe W, Gruemayer ER, Ertelt W, Kotz R, Preuzzer P, Prindull G, Brandeis W, Landbeck G. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988 Feb;6(2):329-37. [http://jco.ascopubs.org/content/6/2/329.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2448428 PubMed]

==MA {{#subobject:cf86ac|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MA: High-dose '''<u>M</u>'''ethotrexate, '''<u>A</u>'''driamycin (Doxorubicin)

===Regimen {{#subobject:243248|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ejcancer.com/article/S0959-8049(06)01072-0/abstract Le Deley et al. 2007 (SFOP OS94)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#MA|Neoadjuvant MA]], then [[Surgery#Surgical_resection|surgery]], with good response
====Chemotherapy, part 1====
*[[Methotrexate (MTX)]] 12,000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1, 8, 15
**Given in D5W 1L with sodium bicarbonate 1 mEq/kg
*[[Doxorubicin (Adriamycin)]] 70 mg/m<sup>2</sup> IV over 6 hours once on day 22

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg PO Q6H x up to 11 doses starting on days 1, 8, 15, starting 20 hours after the completion of [[Methotrexate (MTX)]] infusion
*For methotrexate: hydration & urine alkalinization by PO and IV routes to maintain 1.6 L/m<sup>2</sup> urine output over the first 24 hours and 2 L/m<sup>2</sup> on days 2 & 3, with urine pH greater than 7
*Daily monitoring of methotrexate levels and creatinine

'''28-day cycle for 3 cycles, followed by:'''
====Chemotherapy, part 2====
*[[Methotrexate (MTX)]] 12,000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1, 8, 15
**Given in D5W 1L with sodium bicarbonate 1 mEq/kg

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg PO Q6H x up to 11 doses starting on days 1, 8, 15, 20 hours after the completion of methotrexate infusion
*For methotrexate: hydration & urine alkalinization by PO and IV routes to maintain 1.6 L/m<sup>2</sup> urine output over the first 24 hours and 2 L/m<sup>2</sup> on days 2 & 3, with urine pH greater than 7
*Daily monitoring of methotrexate levels and creatinine

'''21-day course'''

===References===
# Le Deley MC, Guinebretière JM, Gentet JC, Pacquement H, Pichon F, Marec-Bérard P, Entz-Werlé N, Schmitt C, Brugières L, Vanel D, Dupoüy N, Tabone MD, Kalifa C; Société Française d'Oncologie Pédiatrique (SFOP). SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007 Mar;43(4):752-61. Epub 2007 Jan 30. [https://www.ejcancer.com/article/S0959-8049(06)01072-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17267204 PubMed]

==MA-BCD/AP {{#subobject:2ce305|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MA-BCD/AP: High-dose '''<u>M</u>'''ethotrexate, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>C</u>'''yclophosphamide, '''<u>D</u>'''actinomycin alternating with '''<u>A</u>'''driamycin (Doxorubicin) & '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:59841a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM198606193142502 Link et al. 1986]
|style="background-color:#1a9851"|Phase III (E)
|No further treatment
| style="background-color:#1a9850" |Superior RFS
|-
|}
''Note: this regimen is here for historic purposes only.''
====Preceding treatment====
*[[Surgery#Surgical_resection|Surgery]]
====Chemotherapy====
*[[Methotrexate (MTX)]]
*[[Doxorubicin (Adriamycin)]]
*[[Bleomycin (Blenoxane)]] 
*[[Cyclophosphamide (Cytoxan)]]
*[[Dactinomycin (Cosmegen)]]
*[[Doxorubicin (Adriamycin)]]
*[[Cisplatin (Platinol)]]

===References===
# Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, Pritchard J, Malpas JS, Baker AR, Kirkpatrick JA, Ayala AG, Shuster JJ, Abelson HT, Simone JV, Vietti TJ. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986 Jun 19;314(25):1600-6. [https://www.nejm.org/doi/full/10.1056/NEJM198606193142502 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/3520317 PubMed]

==MAP {{#subobject:3b095e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MAP: High-dose '''<u>M</u>'''ethotrexate, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>P</u>'''latinol (Cisplatin)

===Variant #1, 8000/75/100 {{#subobject:6db034|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/10/10/1579.long Bramwell et al. 1992]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Doxorubicin_2|Cisplatin & Doxorubicin]]
|style="background-color:#fc8d59"|Seems to have inferior DFS
|-
|}
''Note: The body of Bramwell et al. 1992 says that methotrexate is given over 4 hours, whereas Bramwell et al. 1992 figure 1's text says that methotrexate is given over 6 hours.''
====Preceding treatment====
*[[#MAP|Neoadjuvant MAP]], then [[Surgery#Surgical_resection|surgery]]
====Chemotherapy====
*[[Methotrexate (MTX)]] 8000 mg/m<sup>2</sup> IV over 4 to 6 hours once on day 1
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV bolus once per day on days 11 to 13
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 11

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 12 mg/m<sup>2</sup> IV Q6H x 10 doses or 15 mg/m<sup>2</sup> PO Q6H x 10 doses, starting 24 hours after the start of methotrexate infusion
**Monitor methotrexate level at "24 hours and 48 hours"--it is unclear in the reference if this is time after the start/end of methotrexate, beginning of leucovorin, or something else
**Methotrexate levels higher than 100 nmol/L at 48 hours required additional leucovorin rescue
*Prehydration for methotrexate: "0.9 NaCl:D5W"--unclear if this means either normal saline or D5W can be used--750 mL/m<sup>2</sup> over 6 hours, with KCl 20 mEq/L
*The volume of fluid for methotrexate is D5W 1000 mL, to be given over 6 hours
*Posthydration for methotrexate: Alternating liters of D5W and NS 3000 mL/m<sup>2</sup> over 24 hours, with KCl 60 mEq/L.
*Sodium bicarbonate 3 g PO Q6H, starting 12 hours before methotrexate, and sodium bicarbonate 167 mmol/L IV until serum methotrexate level is less than 8000 to 10,000 nmol/L. Note: the reference is not clear about when/if PO sodium bicarbonate is stopped, when IV sodium bicarbonate is started, or the administration rate of IV sodium bicarbonate.
*Prehydration for cisplatin: normal saline 400 mL/m<sup>2</sup> and D5W 400 mL/m<sup>2</sup> over 2 hours--the reference did not clarify if these two solutions are given at the same time
*The volume of fluid for cisplatin continuous infusion is 2400 mL/m<sup>2</sup> NS, with KCl 80 mEq/L and mannitol 32,000 mg/m<sup>2</sup>
*Posthydration for cisplatin: D5W 600 mL/m<sup>2</sup> over 6 hours, with KCl 20 mEq/L and mannitol 8000 mg/m<sup>2</sup>; and NS 600 mL/m<sup>2</sup> over 6 hours, with KCl 20 mEq/L, magnesium sulfate 2 mmol/L, and calcium gluconate 0.6 mmol/L--the reference did not clarify if these two solutions are given at the same time. Then D5W 600 mL/m<sup>2</sup> over 12 hours, with KCl 20 mEq/L and mannitol 8000 mg/m<sup>2</sup>.
*With cisplatin, [[Furosemide (Lasix)]] 20 to 40 mg IV if urine output is less than 400 mL/m<sup>2</sup> over 6 hours

'''21-day cycle for 2 cycles'''

===Variant #2, 8000/90/120 {{#subobject:85bced|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19931201)72:11%3C3227::AID-CNCR2820721116%3E3.0.CO;2-C/abstract Bacci et al. 1993]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#MAP|Neoadjuvant MAP]], then [[Surgery#Surgical_resection|surgery]], with at least 90% tumor necrosis in the surgically removed specimen
====Chemotherapy, part 1====
*[[Methotrexate (MTX)]] 8000 mg/m<sup>2</sup> IV over 6 hours once on day 21
*[[Doxorubicin (Adriamycin)]] 45 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 & 2
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup>/day IV continuous infusion over 72 hours, started on day 27 (total dose per cycle: 120 mg/m<sup>2</sup>)

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg IV Q6H x 11 doses on days 22 to 24, starting 24 hours after the start of [[Methotrexate (MTX)]] infusion
*Hydration during and after [[Methotrexate (MTX)]] infusion

'''48-day cycle for 3 cycles, then'''--note: Figure 1 of Bacci et al. 2000 actually depicted the first cycle as being 47 days, and cycles 2 & 3 being 48 days.

====Chemotherapy, part 2====
*[[Doxorubicin (Adriamycin)]] 45 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 & 2

'''Given once after cycle 3'''

===Variant #3, 12,000/60/90 {{#subobject:03bb56|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/6/2/329.long Winkler et al. 1988 (COSS-82)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#MAP|Neoadjuvant MAP]], then [[Surgery#Surgical_resection|surgery]], with good response
====Chemotherapy====
*[[Methotrexate (MTX)]] 12,000 mg/m<sup>2</sup> (maximum dose of 20,000 mg) IV over 4 hours once per day on days 22 & 29
**MTX is dissolved at a concentration of 20,000 mg/L in a solution containing 5% glucose
*[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> IV bolus once per day on days 1 & 2
*[[Cisplatin (Platinol)]] 90 mg/m<sup>2</sup> IV over 4 hours once on day 3

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> PO Q6H x 12 hours once per day on days 23 & 30, starting 24 hours after the completion of methotrexate infusion; additional leucovorin used for delayed methotrexate elimination
*Sodium bicarbonate urine alkalinization prior to high-dose methotrexate
*NS 4.5 L/m<sup>2</sup> on day 1 after methotrexate; NS 3 L/m<sup>2</sup> on day 2, with adjustments made to keep urine pH greater than 7.4
*12 hours of hydration prior to cisplatin & 20 hours of hydration after cisplatin; total amount of fluid given over 36hours of prehydration, cisplatin, and posthydration is NS 6 L/m<sup>2</sup> with mannitol 8 g/L and potassium 20 mval/L.
*Magnesium 180 mg/m<sup>2</sup> PO "per day throughout the whole chemotherapy time"--as described in COSS-80

'''35-day cycle for 2 cycles'''

===Variant #4, 12,000/75/120 {{#subobject:11a698|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052459/ Marina et al. 2016 (EURAMOS-1 poor response)]
|style="background-color:#1a9851"|Phase III (C)
|[[#MAPIE|MAPIE]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[#MAP|Neoadjuvant MAP]] x 2, then [[Surgery#Surgical_resection|surgery]]
====Chemotherapy====
*[[Methotrexate (MTX)]] 12,000 mg/m<sup>2</sup> (maximum dose of 20,000 mg at COG sites) IV over 4 hours once per week in weeks 4 & 5
*[[Doxorubicin (Adriamycin)]] 37.5 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup>/day IV continuous infusion over 72 hours, started on day 1 (total dose per cycle: 120 mg/m<sup>2</sup>)
**COG sites: 60 mg/m<sup>2</sup> IV once per day on days 1 & 2

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> (route/schedule not specified), starting 24 to 48 hours after [[Methotrexate (MTX)]] infusion, continued until MTX level less than 100 nmol/L

'''35-day cycle for 2 cycles'''
====Subsequent treatment====
*[[#MA_2|MA]] x 2

===References===
# '''COSS-82:''' Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, Berger J, Ritter J, Jürgens H, Gerein V, Graf N, Russe W, Gruemayer ER, Ertelt W, Kotz R, Preuzzer P, Prindull G, Brandeis W, Landbeck G. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988 Feb;6(2):329-37. [http://jco.ascopubs.org/content/6/2/329.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2448428 PubMed]
# Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom AT, Voûte PA, Rouesse J, Spooner D, Craft AW, Somers R, Pringle J, Malcolm AJ, van der Eiiken J, Thomas D, Uscinska B, Machin D, van Glabbeke M. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992 Oct;10(10):1579-91. [http://jco.ascopubs.org/content/10/10/1579.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1403038 PubMed]
# '''IOR/OS-2:''' Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, Brach del Prever A, Gherlinzoni F, Mercuri M, Monti C. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993 Dec 1;72(11):3227-38. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19931201)72:11%3C3227::AID-CNCR2820721116%3E3.0.CO;2-C/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8242546 PubMed]
## '''Update:''' Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M, Campanacci M. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000 Dec 15;18(24):4016-27. [http://jco.ascopubs.org/content/18/24/4016.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11118462 PubMed]
# '''EURAMOS-1 good response:''' Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative map: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 2015 Jul 10;33(20):2279-87. Epub 2015 Jun 1. [http://ascopubs.org/doi/full/10.1200/JCO.2014.60.0734 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486345/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26033801 PubMed]
# '''EURAMOS-1 poor response:''' Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KL, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PC, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MC, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 Oct;17(10):1396-1408. Epub 2016 Aug 25. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30214-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052459/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27569442 PubMed]

==MAPI {{#subobject:909a14|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MAPI: High-dose '''<u>M</u>'''ethotrexate, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>P</u>'''latinol (Cisplatin), '''<u>I</u>'''fosfamide
===Regimen {{#subobject:61db3e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/14/7/1126.long Bacci et al. 2003]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#MAPI|Neoadjuvant MAPI]], then [[Surgery#Surgical_resection|surgery]]
====Chemotherapy====
*[[Methotrexate (MTX)]] 12,000 mg/m<sup>2</sup> IV over 4 hours once on day 36
**If 4-hour methotrexate level is less than 10,000 nmol/L, the next cycle's dose is increased by 2000 mg/m<sup>2</sup>
*[[Doxorubicin (Adriamycin)]] 90 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup>/day IV continuous infusion over 48 hours, started on day 43 (total dose per cycle: 120 mg/m<sup>2</sup>) 
*[[Ifosfamide (Ifex)]] 3000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 22, '''given with [[Mesna (Mesnex)]]''' (total dose per cycle: 15,000 mg/m<sup>2</sup>)

====Supportive medications====
*[[Mesna (Mesnex)]] 3000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 22, '''given with [[Ifosfamide (Ifex)]]''' (total dose per cycle: 15,000 mg/m<sup>2</sup>)
*[[Folinic acid (Leucovorin)]] 15 mg (route not specified) Q6H x 11 doses, starting day 36, 24 hours after the start of [[Methotrexate (MTX)]]
*Hydration during and after [[Methotrexate (MTX)]] as described by: Rosen G, Nirenberg A. Chemotherapy for osteogenic sarcoma: an investigative method, not a recipe. Cancer Treat Rep. 1982 Sep;66(9):1687-97. [https://www.ncbi.nlm.nih.gov/pubmed/6981454 PubMed]

'''9-week cycle for 3 cycles'''

===References===
# Bacci G, Briccoli A, Rocca M, Ferrari S, Donati D, Longhi A, Bertoni F, Bacchini P, Giacomini S, Forni C, Manfrini M, Galletti S. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 2003 Jul;14(7):1126-34. [http://annonc.oxfordjournals.org/content/14/7/1126.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12853357 PubMed]

==MAPIE {{#subobject:d9962f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MAPIE: High-dose '''<u>M</u>'''ethotrexate, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>P</u>'''latinol (Cisplatin), '''<u>I</u>'''fosfamide, '''<u>E</u>'''toposide

===Regimen {{#subobject:97ec7e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19931201)72:11%3C3227::AID-CNCR2820721116%3E3.0.CO;2-C/abstract Bacci et al. 1993]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#MAP|Neoadjuvant MAP]], then [[Surgery#Surgical_resection|surgery]], with less than 90% tumor necrosis in the surgically removed specimen
====Chemotherapy, part 1====
*[[Methotrexate (MTX)]] 8000 mg/m<sup>2</sup> IV over 6 hours once on day 42
*[[Doxorubicin (Adriamycin)]] 45 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 & 2
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup>/day IV continuous infusion over 72 hours, started on day 48 (total dose per cycle: 120 mg/m<sup>2</sup>)
*[[Ifosfamide (Ifex)]] 2000 mg/m<sup>2</sup> IV over 90 minutes once per day on days 21 to 25
*[[Etoposide (Vepesid)]] 120 mg/m<sup>2</sup> IV over 60 minutes once per day on days 48 to 50

====Supportive medications====
*[[Mesna (Mesnex)]] with [[Ifosfamide (Ifex)]]; no actual dose is listed in the reference
*[[Folinic acid (Leucovorin)]] 15 mg IV Q6H x 11 doses on days 43 to 45, starting 24 hours after the start of [[Methotrexate (MTX)]] infusion
*Hydration during and after [[Methotrexate (MTX)]] infusion

'''69-day cycle for 3 cycles, then'''--note: Figure 1 of Bacci et al. 2000 actually depicted the first cycle as being 68 days, and cycles 2 & 3 being 69 days.

====Chemotherapy, part 2====
*[[Doxorubicin (Adriamycin)]] 45 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 & 2

'''Given once after postoperative chemotherapy cycle 3'''

===References===
# '''IOR/OS-2:''' Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, Brach del Prever A, Gherlinzoni F, Mercuri M, Monti C. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993 Dec 1;72(11):3227-38. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19931201)72:11%3C3227::AID-CNCR2820721116%3E3.0.CO;2-C/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8242546 PubMed]
## '''Update:''' Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M, Campanacci M. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000 Dec 15;18(24):4016-27. [http://jco.ascopubs.org/content/18/24/4016.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11118462 PubMed]
# '''EURAMOS-1 poor response:''' Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KL, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PC, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MC, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 Oct;17(10):1396-1408. Epub 2016 Aug 25. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30214-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052459/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27569442 PubMed]

==M-BCD {{#subobject:67c944|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
M-BCD: High-dose '''<u>M</u>'''ethotrexate, '''<u>B</u>'''leomycin, '''<u>C</u>'''yclophosphamide, '''<u>D</u>'''actinomycin

===Regimen {{#subobject:3696a1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/6/2/329.long Winkler et al. 1988 (COSS-82)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Note: The exact schedule is unclear based on limited information in the reference, as schedule of doses is primarily extrapolated from Figure 1, which does not contain clear delineations in time.''
====Preceding treatment====
*[[#M-BCD|Neoadjuvant M-BCD]], then [[Surgery#Surgical_resection|surgery]], with good response
====Chemotherapy====
*[[Methotrexate (MTX)]] 12,000 mg/m<sup>2</sup> (maximum dose of 20,000 mg) IV over 4 hours once per day on days 15 & 22
**MTX is dissolved at a concentration of 20,000 mg/L in a solution containing 5% glucose
*[[Bleomycin (Blenoxane)]] 15 mg/m<sup>2</sup> IV bolus once per day on days 1 & 2
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV bolus once per day on days 1 & 2
*[[Dactinomycin (Cosmegen)]] 0.6 mg/m<sup>2</sup> IV bolus once per day on days 1 & 2

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> PO Q6H x 12 hours once per day on days 16 & 23, starting 24 hours after the completion of methotrexate infusion; additional leucovorin used for delayed methotrexate elimination
*Sodium bicarbonate urine alkalinization prior to high-dose methotrexate
*NS 4.5 L/m<sup>2</sup> on day 1 after methotrexate; NS 3 L/m<sup>2</sup> on day 2, with adjustments made to keep urine pH greater than 7.4

'''35-day cycle for 2 cycles'''

===References===
# Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987 Jan;5(1):21-6. [http://ascopubs.org/doi/abs/10.1200/JCO.1987.5.1.21 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/3543236 PubMed]
## '''Update:''' Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC, Tap WD. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 2012 Dec 1;118(23):5888-93. Epub 2012 May 30. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.27651 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22648705 PubMed]
# '''COSS-82:''' Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, Berger J, Ritter J, Jürgens H, Gerein V, Graf N, Russe W, Gruemayer ER, Ertelt W, Kotz R, Preuzzer P, Prindull G, Brandeis W, Landbeck G. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988 Feb;6(2):329-37. [http://jco.ascopubs.org/content/6/2/329.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2448428 PubMed]

==M-EI {{#subobject:79b8f9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
M-EI: '''<u>'''ethotrexate, '''<u>E</u>'''toposide, '''<u>I</u>'''fosfamide
===Regimen {{#subobject:7fc4e3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ejcancer.com/article/S0959-8049(06)01072-0/abstract Le Deley et al. 2007 (SFOP OS94)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#M-EI|Neoadjuvant M-EI]], then [[Surgery#Surgical_resection|surgery]], with good response
====Chemotherapy, part 1====
*[[Methotrexate (MTX)]] 12,000 mg/m<sup>2</sup> IV over 4 hours once per week on weeks 1, 2, 3
**Given in D5W 1L with sodium bicarbonate 1 mEq/kg
*[[Etoposide (Vepesid)]] 75 mg/m<sup>2</sup> IV over 60 minutes once per day on days 22 to 25 (week 4)
**Given in NS 250 to 500 mL
*[[Ifosfamide (Ifex)]] 3000 mg/m<sup>2</sup> IV over 3 hours once per day on days 22 to 25 (week 4), '''given during [[Mesna (Mesnex)]] infusion''' (total dose per cycle: 12,000 mg/m<sup>2</sup>)
**Given in NS 250 to 500 mL

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg PO Q6H x up to 11 doses on weeks 1, 2, 3, starting 20 hours after the completion of [[Methotrexate (MTX)]] infusion
*For methotrexate: hydration & urine alkalinization by PO and IV routes to maintain 1.6 L/m<sup>2</sup> urine output over the first 24 hours and 2 L/m<sup>2</sup> on days 2 & 3, with urine pH greater than 7
*Daily monitoring of methotrexate levels and creatinine
*[[Mesna (Mesnex)]] 3600 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 22 (week 4) (total dose per cycle: 14,400 mg/m<sup>2</sup>)
*Up to 2 L/day hydration with ifosfamide & mesna

'''28-day cycle for 3 cycles, followed by:'''

====Chemotherapy, part 2====
*[[Methotrexate (MTX)]] 12,000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1, 8, 15
**Given in D5W 1L with sodium bicarbonate 1 mEq/kg

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg PO Q6H x up to 11 doses starting on days 1, 8, 15, 20 hours after the completion of methotrexate infusion
*For methotrexate: hydration & urine alkalinization by PO and IV routes to maintain 1.6 L/m<sup>2</sup> urine output over the first 24 hours and 2 L/m<sup>2</sup> on days 2 & 3, with urine pH greater than 7
*Daily monitoring of methotrexate levels and creatinine

'''21-day course'''

===References===
# '''SFOP OS94:''' Le Deley MC, Guinebretière JM, Gentet JC, Pacquement H, Pichon F, Marec-Bérard P, Entz-Werlé N, Schmitt C, Brugières L, Vanel D, Dupoüy N, Tabone MD, Kalifa C; Société Française d'Oncologie Pédiatrique (SFOP). SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007 Mar;43(4):752-61. Epub 2007 Jan 30. [https://www.ejcancer.com/article/S0959-8049(06)01072-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17267204 PubMed]
# '''OS2006:''' Piperno-Neumann S, Le Deley MC, Rédini F, Pacquement H, Marec-Bérard P, Petit P, Brisse H, Lervat C, Gentet JC, Entz-Werlé N, Italiano A, Corradini N, Bompas E, Penel N, Tabone MD, Gomez-Brouchet A, Guinebretière JM, Mascard E, Gouin F, Chevance A, Bonnet N, Blay JY, Brugières L; Sarcoma Group of UNICANCER; French Society of Pediatric Oncology (SFCE); French Sarcoma Group (GSF-GETO). Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016 Aug;17(8):1070-1080. Epub 2016 Jun 17. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30096-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27324280 PubMed]
## '''Update:''' Gaspar N, Occean BV, Pacquement H, Bompas E, Bouvier C, Brisse HJ, Castex MP, Cheurfa N, Corradini N, Delaye J, Entz-Werlé N, Gentet JC, Italiano A, Lervat C, Marec-Berard P, Mascard E, Redini F, Saumet L, Schmitt C, Tabone MD, Verite-Goulard C, Le Deley MC, Piperno-Neumann S, Brugieres L; SFCE (Société Française des Cancers de l'Enfant et l'adolescent); GSF-GETO (Groupe Sarcome Français); UNICANCER sarcoma group. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. Eur J Cancer. 2018 Jan;88:57-66. Epub 2017 Nov 28. [https://www.ejcancer.com/article/S0959-8049(17)31339-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29190507 PubMed]

==Methotrexate & Vincristine {{#subobject:606364|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:8f64e5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM197411072911902 Jaffe et al. 1974]
|style="background-color:#91cf61"|Non-randomized
|-
|}
''Of historic interest.''
====Preceding treatment====
*[[Surgery#Surgical_resection|Surgery]]
====Chemotherapy====
*[[Methotrexate (MTX)]]
*[[Vincristine (Oncovin)]]

====Supportive medications====
*[[Folinic acid (Leucovorin)]]

'''21-day cycles for up to 2 years'''
===References===
# Jaffe N, Frei E 3rd, Traggis D, Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med. 1974 Nov 7;291(19):994-7. [https://www.nejm.org/doi/full/10.1056/NEJM197411072911902 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/4606174 PubMed]

=Maintenance after upfront therapy=

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486345/ Bielack et al. 2015 (EURAMOS-1 good response)]
| style="background-color:#1a9851" |Phase III (C)
|Interferon alfa-2B
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''No further treatment.''
====Preceding treatment====
*[[#MAP|Neoadjuvant MAP]] x 2, then [[Surgery#Surgical_resection|surgery]], then adjuvant [[#MAP_2|MAP]] x 2, then [[#MA_2|MA]] x 2
===References===
# '''EURAMOS-1 good response:''' Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative map: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 2015 Jul 10;33(20):2279-87. Epub 2015 Jun 1. [http://ascopubs.org/doi/full/10.1200/JCO.2014.60.0734 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486345/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26033801 PubMed]

=Relapsed, refractory, or metastatic, first-line=

==Cisplatin & Doxorubicin {{#subobject:418c69|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
AP: '''<u>A</u>'''driamycin (Doxorubicin) & '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:60d18a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395371/ Bramwell et al. 1997 (EOI 80831/MRC B002)]
|style="background-color:#1a9851"|Phase III (E)
|[[#MAP_3|MAP]]
|style="background-color:#d73027"|Inferior OS
|-
|}
''Note: the authors state that "[i]t is likely that random bias in the population..accounts for the difference in outcome favoring the three-drug treatment in patients with metastatic disease."''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV bolus once per day on days 1 to 3

====Supportive medications====
*Prehydration: normal saline 400 mL/m<sup>2</sup> and D5W 400 mL/m<sup>2</sup> over 2 hours--the reference did not clarify if these two solutions are given at the same time
*The volume of fluid for cisplatin continuous infusion is 2400 mL/m<sup>2</sup> NS, with KCl 80 mEq/L and mannitol 32,000 mg/m<sup>2</sup>
*Posthydration: D5W 600 mL/m<sup>2</sup> over 6 hours, with KCl 20 mEq/L and mannitol 8000 mg/m<sup>2</sup>; and NS 600 mL/m<sup>2</sup> over 6 hours, with KCl 20 mEq/L, magnesium sulfate 2 mmol/L, and calcium gluconate 0.6 mmol/L--the reference did not clarify if these two solutions are given at the same time. Then D5W 600 mL/m<sup>2</sup> over 12 hours, with KCl 20 mEq/L and mannitol 8000 mg/m<sup>2</sup>.
*[[Furosemide (Lasix)]] 20 to 40 mg IV if urine output is less than 400 mL/m<sup>2</sup> over 6 hours

'''21-day cycle for 6 cycles'''

===References===
# '''EOI 80831/MRC B002:''' Bramwell VH, Burgers MV, Souhami RL, Taminiau AH, Van Der Eijken JW, Craft AW, Malcolm AJ, Uscinska B, Kirkpatrick AL, Machin D, Van Glabbeke MM. A randomized comparison of two short intensive chemotherapy regimens in children and young adults with osteosarcoma: results in patients with metastases: a study of the European Osteosarcoma Intergroup. Sarcoma. 1997;1(3-4):155-60. [https://www.hindawi.com/journals/sarcoma/1997/974904/abs/ link to original article] '''contains verified partial protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395371/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18521218 PubMed]

==Doxorubicin monotherapy {{#subobject:8a4535|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:dc69eb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://jamanetwork.com/journals/jama/article-abstract/344236 Cores et al. 1972]
| style="background-color:#ffffbe" |Non-randomized, <20 pts
|-
|}
''Of historic interest.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]]
===References===
# Cores EP, Holland JF, Wang JJ, Sinks LF. Doxorubicin in disseminated osteosarcoma. JAMA. 1972 Sep 4;221(10):1132-8. [https://jamanetwork.com/journals/jama/article-abstract/344236 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/4512088 PubMed]

==MAP {{#subobject:ed2dcf|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MAP: High-dose '''<u>M</u>'''ethotrexate, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:d359c6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395371/ Bramwell et al. 1997 (EOI 80831/MRC B002)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Doxorubicin_3|Cisplatin & Doxorubicin]]
|style="background-color:#1a9850"|Superior OS
|-
|}
''Note: the authors state that "[i]t is likely that random bias in the population..accounts for the difference in outcome favoring the three-drug treatment in patients with metastatic disease."''
====Chemotherapy====
*[[Methotrexate (MTX)]] 8000 mg/m<sup>2</sup> IV over 4 hours once on day 1
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV bolus once per day on days 11 to 13
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 11

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 12 mg/m<sup>2</sup> IV Q6H x 10 doses or 15 mg/m<sup>2</sup> PO Q6H x 10 doses, starting 24 hours after the start of methotrexate infusion
**Monitor methotrexate level at "24 hours and 48 hours"--it is unclear in the reference if this is time after the start/end of methotrexate, beginning of leucovorin, or something else
**Methotrexate levels higher than 100 nmol/L at 48 hours required additional leucovorin rescue
*Prehydration for methotrexate: "0.9 NaCl:D5W"--unclear if this means either normal saline or D5W can be used--750 mL/m<sup>2</sup> over 6 hours, with KCl 20 mEq/L
*The volume of fluid for methotrexate is D5W 1000 mL, to be given over 6 hours
*Posthydration for methotrexate: Alternating liters of D5W and NS 3000 mL/m<sup>2</sup> over 24 hours, with KCl 60 mEq/L.
*Sodium bicarbonate 3 g PO Q6H, starting 12 hours before methotrexate, and sodium bicarbonate 167 mmol/L IV until serum methotrexate level is less than 8000 to 10,000 nmol/L. Note: the reference is not clear about when/if PO sodium bicarbonate is stopped, when IV sodium bicarbonate is started, or the administration rate of IV sodium bicarbonate.
*Prehydration for cisplatin: normal saline 400 mL/m<sup>2</sup> and D5W 400 mL/m<sup>2</sup> over 2 hours--the reference did not clarify if these two solutions are given at the same time
*The volume of fluid for cisplatin continuous infusion is 2400 mL/m<sup>2</sup> NS, with KCl 80 mEq/L and mannitol 32,000 mg/m<sup>2</sup>
*Posthydration for cisplatin: D5W 600 mL/m<sup>2</sup> over 6 hours, with KCl 20 mEq/L and mannitol 8000 mg/m<sup>2</sup>; and NS 600 mL/m<sup>2</sup> over 6 hours, with KCl 20 mEq/L, magnesium sulfate 2 mmol/L, and calcium gluconate 0.6 mmol/L--the reference did not clarify if these two solutions are given at the same time. Then D5W 600 mL/m<sup>2</sup> over 12 hours, with KCl 20 mEq/L and mannitol 8000 mg/m<sup>2</sup>.
*With cisplatin, [[Furosemide (Lasix)]] 20 to 40 mg IV if urine output is less than 400 mL/m<sup>2</sup> over 6 hours

'''21-day cycle for 4 cycles'''

===References===
# '''EOI 80831/MRC B002:''' Bramwell VH, Burgers MV, Souhami RL, Taminiau AH, Van Der Eijken JW, Craft AW, Malcolm AJ, Uscinska B, Kirkpatrick AL, Machin D, Van Glabbeke MM. A randomized comparison of two short intensive chemotherapy regimens in children and young adults with osteosarcoma: results in patients with metastases: a study of the European Osteosarcoma Intergroup. Sarcoma. 1997;1(3-4):155-60. '''contains verified partial protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395371/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18521218 PubMed]

=Relapsed, refractory, or metastatic, subsequent lines=

==Cyclophosphamide & Etoposide {{#subobject:7bb7cb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:1d31a0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.24368/full Berger et al. 2009]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 4000 mg/m<sup>2</sup> IV over 3 hours once on day 1
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV over 60 minutes twice per day on days 2 to 4 (total dose: 600 mg/m<sup>2</sup>)

====Supportive medications====
*[[Mesna (Mesnex)]] 1400 mg/m<sup>2</sup> IV three times per day on day 1: before, 4 hours after, and 8 hours after [[Cyclophosphamide (Cytoxan)]]
**With mesna, 3000 mL/m<sup>2</sup> hydration

'''At least 21-day cycle for 2 cycles, then restaging'''
====Subsequent treatment====
*Patients with no progression received an experimental protocol with:
**Samarium-153 10 mCi/kg and/or carboplatin & etoposide based on status of bone metastases ''(no further details about dose/schedule given)''
**Progression-free patients received reduced intensity stem cell transplant (preferably from a matched sibling donor (MSD))
**Patients with no MSD received IL-2 maintenance, 5 days a week every 2 weeks x 12 cycles (reference did not specify if a cycle was 2 weeks, 4 weeks, or another length)

===References===
# Berger M, Grignani G, Ferrari S, Biasin E, Brach del Prever A, Aliberti S, Saglio F, Aglietta M, Fagioli F. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Cancer. 2009 Jul 1;115(13):2980-7. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.24368/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19452540 PubMed]

==Cyclophosphamide & Topotecan {{#subobject:533aef|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:950899|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/19/15/3463.long Saylors et al. 2001]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 250 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5, '''given first'''
*[[Topotecan (Hycamtin)]] 0.75 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5, '''given second'''

====Supportive medications====
*500 mL/m/2 fluids IV or PO 2 to 4 hours before chemotherapy
*Antiemetics as premedication before chemotherapy
*3 liters/m<sup>2</sup> IV or PO over 24 hours after chemotherapy
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day 6, to continue until ANC is at least 1500/uL after the nadir period

'''21-day cycle for 12 to 14 cycles'''

===References===
# Saylors RL 3rd, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, Harris MB, Hayashi R, Vietti TJ; Pediatric Oncology Group. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001 Aug 1;19(15):3463-9. [http://jco.ascopubs.org/content/19/15/3463.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11481351 PubMed]

==Docetaxel & Gemcitabine {{#subobject:55d598|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:c3c88e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.23586/full Navid et al. 2008]
|style="background-color:#ffffbe"|Retrospective
|-
|}
''17 of the 22 patients in this retrospective review had osteosarcoma.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 to 100 mg/m<sup>2</sup> IV over 60 minutes once on day 8, '''given second'''
*[[Gemcitabine (Gemzar)]] 675 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1 & 8, '''given first'''

====Supportive medications====
*[[Ondansetron (Zofran)]] prior to chemotherapy on days 1 & 8
*[[Dexamethasone (Decadron)]] starting either the day before or the day of [[Docetaxel (Taxotere)]], and continued for 2 days after [[Docetaxel (Taxotere)]]
*H1 or H2 blockers such as [[Diphenhydramine (Benadryl)]] and [[Ranitidine (Zantac)]] prior to chemotherapy on days 1 & 8 per physician discretion
*Some patients received [[Filgrastim (Neupogen)]] starting on day 9

'''21-day cycles'''

===References===
# '''Retrospective:''' Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, Daw NC. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008 Jul 15;113(2):419-25. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.23586/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18484657 PubMed]

==Gemcitabine monotherapy {{#subobject:2a9006|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:fb0d84|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.springerlink.com/content/twcbtb7melmmxtl4/ Merimsky et al. 2000]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] as follows:
**Cycle 1: 1000 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
**Cycle 2 onwards: [[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===References===
# Merimsky O, Meller I, Flusser G, Kollender Y, Issakov J, Weil-Ben-Arush M, Fenig E, Neuman G, Sapir D, Ariad S, Inbar M. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol. 2000;45(2):177-81. [http://www.springerlink.com/content/twcbtb7melmmxtl4/ link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10663634 PubMed]

==ICE {{#subobject:3fe1fa|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ICE: '''<u>I</u>'''fosfamide, '''<u>C</u>'''arboplatin, '''<u>E</u>'''toposide
===Regimen {{#subobject:61c68a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/pbc.20227/abstract Van Winkle et al. 2005]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: the reference did not mention [[Mesna (Mesnex)]] being used.''
====Chemotherapy====
*[[Ifosfamide (Ifex)]] 1800 mg/m<sup>2</sup> IV once per day on days 1 to 5
*[[Carboplatin (Paraplatin)]] 400 mg/m<sup>2</sup> IV "for 2 days"
**Note: the reference did not explicitly say which 2 days carboplatin should be given on
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 5

====Supportive medications====
*Depending on the study the patients were enrolled on, they received one of the following:
**CCG-0894: [[Filgrastim (Neupogen)]] 5 or 10 mcg/kg SC once per day, starting 24 hours after completing ICE, and to continue until day 18 if ANC is at least 1000/uL, or until ANC is at least 1000/uL above nadir, whichever comes later
**CCG-0924: PIXY 321 at doses of 500/750/1000 mcg/m<sup>2</sup> SC once per day or 500 mcg/m<sup>2</sup> SC twice per day, starting on day 5 and to continue until day 18 unless ANC reached 20,000/uL or platelet count is at least 900 x 10<sup>9</sup>/L for 2 days between days 13 to 18, or until ANC is at least 1000/uL and platelet count is at least 100 x 10<sup>9</sup>/L, whichever comes later
**CCG-0931: [[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day and IL-6 at 2.5, 3.75, or 5.0 mcg/kg SC twice per day, starting 24 hours after completing ICE. Filgrastim is continued until ANC is at least 1000/uL, and IL-6 is continued until platelets are at least 100 x 10<sup>9</sup>/L for 2 consecutive days or until day 35, whichever comes sooner.

'''21-day cycles''', with next cycle starting as soon as ANC is at least 1000/uL and platelet count is at least 100 x 10<sup>9</sup>/L
====Subsequent treatment====
*Resection of disease was allowed after 4 cycles based on patient's response to ICE

===References===
# Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, Reaman G, Cairo MS. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer. 2005 Apr;44(4):338-47. [https://onlinelibrary.wiley.com/doi/10.1002/pbc.20227/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15503297 PubMed]

==IE {{#subobject:29f233|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
IE: '''<u>I</u>'''fosfamide & '''<u>E</u>'''toposide
===Regimen {{#subobject:659e8c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ejcancer.com/article/S0959-8049(96)00439-X/abstract Gentet et al. 1997]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Ifosfamide (Ifex)]] 3000 mg/m<sup>2</sup> IV over 3 hours once per day on days 1 to 4
**Given in D5W 250 to 500 mL
*[[Etoposide (Vepesid)]] 75 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 4
**Given in D5W 250 to 500 mL

====Supportive medications====
*[[Mesna (Mesnex)]] 3600 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 14,400 mg/m<sup>2</sup>)
*At least 2000 mL/m<sup>2</sup>/day of hydration with chemotherapy

'''21 to 28-day cycle for 2 cycles, with next cycle starting when ANC greater than 1500/uL and platelet count greater than 100 x 10<sup>9</sup>/L'''

===References===
# Gentet JC, Brunat-Mentigny M, Demaille MC, Pein F, Avet-Loiseau H, Berger C, De Lumley L, Pacquement H, Schmitt C, Sariban E, Pillon P, Bernard JL, Kalifa C. Ifosfamide and etoposide in childhood osteosarcoma: a phase II study of the French Society of Paediatric Oncology. Eur J Cancer. 1997 Feb;33(2):232-7. [https://www.ejcancer.com/article/S0959-8049(96)00439-X/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9135494 PubMed]

==Samarium-153 with stem cell support {{#subobject:26224a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:8c0a7f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/20/1/189.long Anderson et al. 2002]
|style="background-color:#ffffbe"|Phase I
|-
|}

*Peripheral blood progenetor cell (PBPC) or bone marrow harvest and cryopreservation of at least 2 x 10<sup>6</sup> CD34+ cells/kg
====Radiotherapy====
*[[Samarium-153 (Quadramet)]] 30 mCi/kg IV once on day 0

====Supportive medications====
*Growth factor support with ONE of the following started when ANC less than 1000/uL:
**[[Filgrastim (Neupogen)]]
**[[Sargramostim (Leukine)]] 

'''On day +14, infuse peripheral blood progenetor cell (PBPC) or bone marrow cells'''

===References===
# '''Phase 1:''' Anderson PM, Wiseman GA, Dispenzieri A, Arndt CA, Hartmann LC, Smithson WA, Mullan BP, Bruland OS. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002 Jan 1;20(1):189-96. [http://jco.ascopubs.org/content/20/1/189.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11773169 PubMed]

[[Category:Osteosarcoma regimens]]
[[Category:Disease-specific pages]]
[[Category:Bone sarcomas]]
[[Category:Pediatric cancers]]
